Bill of Health
APRIL 24, 2023
Yet Dmitry Karshtedt held otherwise at the ASLME Health Law Professor’s Conference in Atlanta, GA in 2017. Glenn Cohen’s Health Law Policy, Bioethics, and Biotechnology Workshop at HLS. As such, product hopping is generally viewed as problematic. My talk was titled “Legal Approaches to Ensuring Timely Generic Drug Availability.”
Bill of Health
OCTOBER 28, 2024
They completed a postdoctoral fellowship in the Department of Bioethics at the Case Western Reserve University School of Medicine and received their PhD in Comparative Literature from the University of Pennsylvania. Harrison M.A., is a licensed marriage and family therapist, researcher, and bioethicist.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
DECEMBER 6, 2024
Devices must primarily comply with Regulations (EU) 2017/745 on Medical Devices and 2017/746 on In Vitro Diagnostic Medical Devices. There is no specific regulation for quantum technology in healthcare, though the European Declaration on Quantum Technologies acknowledges its importance.
Bill of Health
JANUARY 29, 2024
In its origins, Psymposia was the programming partner for the largest psychedelic conference of its time—MAPS’s Psychedelic Science 2017—where it curated a full schedule of speakers on an eponymous stage. Image: Psychedelic Science 2017 signage, courtesy of Brian Normand.
Bill of Health
JUNE 13, 2022
One study found that an ethics course led recipients to engage in more thorough — but not necessarily better — reasoning, while another found that evaluators disagreed so often that it was nearly impossible to achieve consensus about students’ performances.
Health Populi
AUGUST 12, 2021
By 2022, CTA projects that connected exercise equipment will reach sales of 2.5 million units with revenues of $4.5 billion.
Health Populi
MAY 20, 2021
Year-on-year, different spikes and ups-and-downs call out for special mention, such as: Pharma’s 13-point steep dive to 38% between 2017 and 2018, dramatically recovering by 9 points in the last year to 47% [with the wild card here of whether U.S. to approve Medicare’s negotiation of drug prices with pharmaceutical companies].
Expert insights. Personalized for you.
317 
Let's personalize your content